Sanofi-Aventis Czech Republic made a net profit of CZK 1.19 mil under revenues of CZK 6,120 mil in 2014, down -98.2% and -6.30%, respectively, when compared to the last year. This translates into a net margin of 0.019%.
Historically, the firm’s net profit reached an all time high of CZK 73.4 mil in 2005 and an all time low of CZK -2.02 mil in 2004. Since 2009, the firm's net profit has increased -97.3% or -51.5% a year on average.
On the operating level, EBITDA reached CZK 17.0 mil, up -82.8% when compared to the previous year. Over the last five years, company's EBITDA has grown -25.0% a year on average.
As far as Sanofi-Aventis Czech Republic's peers are concerned, Roche Czech Republic posted net and EBITDA margin of 2.17% and 6.07%, respectively in 2014, Bayer Czech Republic generated margins of 2.64% and 3.53% and Amgen Czech Republic's profit margin reached 6.36% on the net and 8.55% on the EBITDA level in 2014.